Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lo

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.

Shares of Ichor Holdings, Ltd. (NASDAQ:ICHR) fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results and issued second-quarter guidance below estimates.

Ichor Hldgs reported quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $244.47 million which missed the analyst consensus estimate of $244.95 million.

Ichor Holdings shares dipped 14.8% to $17.75 in the pre-market trading session.

Here are some other stocks moving lower in pre-market trading.

Hyperscale Data, Inc. (NYSE:GPUS) dipped 17.2% to $6.42 in pre-market trading. Hyperscale Data shares jumped 466% on Monday after the company issued FY25 sales guidance.
Immutep Limited (NASDAQ:IMMP) fell 13.3% to $2.16 in pre-market trading. Immutep shares jumped over 45% on Monday after the company provided updates for cohort B of its Tacti-003 Phase IIb trial.
Palantir Technologies Inc. (NASDAQ:PLTR) fell 8.4% to $113.45 in pre-market trading. Palantir reported in-line earnings for its first quarter on Monday. Palantir reported first-quarter revenue of $883.86 million, beating analyst estimates of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates. The company also raised its full-year guidance.
Castle Biosciences, Inc. (NASDAQ:CSTL) fell 7.7% to $17.30 in pre-market trading following downbeat quarterly earnings.
Arcus Biosciences, Inc. (NYSE:RCUS) fell 7.1% to $8.31 in pre-market trading.
Fabrinet (NYSE:FN) fell 6.8% to $206.00 in today's pre-market trading after the company reported third-quarter results and issued fourth-quarter guidance with its midpoint below estimates.
EverQuote, Inc. (NASDAQ:EVER) declined 5.1% to $25.00 in pre-market trading following first-quarter results.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) fell 5% to $475.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results.